FDA clears Abiomed devices for circulatory support

Justine Varieur Cadet | | Health Imaging | Screening
Abiomed, a provider of heart support technologies, has received 510(k) clearance from the FDA for its Impella 5.0 and Impella LD Circulatory Support Devices, designating they can provide circulatory support for up to six hours.

Similar to the Impella 2.5, which received 510(k) clearance on June 2, 2008, for partial circulatory support for periods of up to six hours, the Impella 5.0 and Impella LD devices are minimally invasive catheter-based pumps, according to the Danvers, Mass.-based company. The pump is approximately the size of a pencil with a small, nine French (3 mm diameter) catheter, which drives up to five liters of blood flow per minute.

Justine Varieur Cadet

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.